Top Markets
Coin of the day
Autolus Therapeutics plc Autolus Therapeutics plc

Autolus Therapeutics plc

AUTL
Classificação em ações #12088
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily... Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Preço da ação
$2.34
Última sincronização: 2026-08-28
Valor de mercado
$621.44M
Variação (1 dia)
-1.06%
Variação (1 ano)
55.67%
País
GB
Negociar Autolus Therapeutics plc (AUTL)

Categoria

Histórico de preços das ações de Autolus Therapeutics plc (AUTL)
Preço de fecho mais alto: $2.28 em 2026-08-01

Preço de fecho mais baixo: $26.43 em 2018-06-01
Histórico de preços das ações da Autolus Therapeutics plc de 2018 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) -2.43%
2025 -37.78%
2024 -48.76%
2023 131.99%
2022 -61.84%
2021 -37.82%
2020 -34.48%
2019 -57.61%
2018 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.20 -12.94%
AU
$138.18 473.58%
US
$759.27 7.20%
CH